Kurzübersicht für Fms-Related tyrosine Kinase 3 (FLT3) (N-Term) Peptid (ABIN5512790)
Target
FLT3
(Fms-Related tyrosine Kinase 3 (FLT3))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB)
Protein Region
N-Term
Sequenz
Synthetic peptide located within the following region: < a href='http://www.ncbi.nlm.nih.gov/blast/Blast.cgi?PROGRAM=blastp&CLIENT=web&SERVICE=plain&PAGE=Proteins&CMD=Put&DATABASE=nr&CDD_SEARCH=1&AUTO_FORMAT=Semi-auto&SHOW_OVERVIEW=on&SHOW_LINKOUT=on&GET_S
Produktmerkmale
This is a synthetic peptide designed for use in combination with anti-FLT3 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Lagerung
-20 °C
Informationen zur Lagerung
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target
FLT3
(Fms-Related tyrosine Kinase 3 (FLT3))
Hintergrund
This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.